Varian, Inc. Reports Fourth Quarter 20...(iscal Quarter Ended Fiscal Year Ended ...),Health

Date:11/4/2009

iscal Quarter Ended Fiscal Year Ended ----------------- ----------------- October 2, October 3, October 2, October 3, 2009 2008 2009 2008 ------- ------- ------- ------- TOTAL COMPANY (Continued) ------------------------- Net Earnings U.S. GAAP as reported $ 1,940 $20,377 $38,620 $65,114 Adjustments: Acquisition-related in- process research and development charges - 215 - 1,703 Acquisition-related intangible amortization 1,217 1,526 4,925 5,617 Acquisition-related inventory write-up amortization 52 97 94 923 Costs related to pending acquisition by Agilent 8,110 - 8,110 - Impairment of private company equity investment - - - 1,871 Restructuring and other related costs 209 763 6,297 3,461 ------- ------- ------- ------- As adjusted $11,528 $22,978 $58,046 $78,689 ======= ======= ======= ======= Diluted Earnings Per Share U.S. GAAP as reported $ 0.07 $ 0.69 $ 1.34 $ 2.17 Adjustments: Acquisition-related in- process research and development charges - 0.01 - 0.06 Acquisition-related intangible amortization 0.04 0.05 0.17 0.18 Acquisition-related inventory write-up amortization 0.00 0.00 0.00 0.03 Costs related to pending acquisition by Agilent 0.28 - 0.28 -
'/>"/>

SOURCE Varian, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Related medicine technology :

1. Varian, Inc. to Release Fourth Quarter and Full Fiscal Year 2009 Financial Results
2. Varian, Inc. Delivers a Productivity Increase of Up to 100% With Its 710-ES Series ICP-OES
3. 96-Well Filtration Plate From Varian, Inc. Improves Sensitivity and Precision for Trace Bio-Analysis by LC/MS
4. Thoratec Reports 14 Percent Growth in Cardiovascular Division Sales as Third Quarter Revenues Increase Nine Percent
5. Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
6. Cambrex Reports Third Quarter 2009 Results
7. Regeneron Reports Third Quarter 2009 Financial and Operating Results
8. Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
9. Uroplasty Reports Results for Second Quarter FY2010
10. Shire Reports Tolerability and Clinical Effects Results of Daytrana(R) (methylphenidate transdermal system) from Study in Adolescents with ADHD
11. Mettler-Toledo International Inc. Reports Third Quarter 2009 Results